Amendments to the Specification

Please amend Paragraph [0013] as follows:

[0001] In certain embodiments, Xaa1 is acetylated, and typically is Ac-Ile. In another embodiment, Xaa3 is Ala. In other embodiments, Xaa2 is an analog of Trp comprising a substituted or unsubstituted aromatic ring component, preferably comprising a bicyclic ring, (e.g., indole, naphthyl ~~napthyl~~)or two rings (e.g., dibenzoyl). In exemplary embodiments, the analog of Trp is 2-naphthlyalanine ~~2-napthylalanine~~, 1-naphthylalanine ~~1-naphthylalanine~~, 2-indanylglycine carboxylic acid, dihydrotryptophan or benzoylphenylalanine.

Please amend Paragraph [0045] as follows:

[0002] TABLE 1.

Peptide	Sequence	SEQ ID NO:	Activity over Compstatin
Compstatin	*H*-ICVVQDWGHHRCT-*CONH2*	1	*
Ac-Compstatin	*Ac*-ICVVQDWGHHRCT-*CONH2*	2	3xmore
Ac- 4Y,9A	*Ac*-ICV**Y**QDWG**A**HRCT-*CONH2*	3	19xmore
Ac- 4W,9A -OH	*Ac*-ICV**W**QDWG**A**HRCT-*COOH*	4	25xmore
Ac- 4W,9A	*Ac*-ICV**W**QDWG**A**HRCT-*CONH2*	5	55xmore
Ac- 4W,9A13dT -OH	*Ac*-ICV**W**QDWG**A**HRC**dT**-*COOH*	6	55xmore
Ac- 4(2-Nal),9A	*Ac*-ICV**(2-Nal)**QDWG**A**HRCT-*CONH2*	7	66xmore
Ac- 4(2-Nal),9A -OH	*Ac*-ICV**(2-Nal)**QDWG**A**HRCT-*COOH*	8	39xmore
Ac- 4(1-Nal),9A -OH	*Ac*-ICV**(1-Nal)**QDWG**A**HRCT-*COOH*	9	23xmore
Ac- 4Igl,9A	*Ac*-ICV**Igl**QDWG**A**HRCT-*CONH2*	10	55xmore
Ac- 4Igl,9A -OH	*Ac*-ICV**Igl**QDWG**A**HRCT-*COOH*	11	55xmore
Ac- 4Dht,9A -OH	*Ac*-ICV**Dht**QDWG**A**HRCT-*COOH*	12	9xmore
Ac- 4(Bpa),9A -OH	*Ac*-ICV**(Bpa)**QDWG**A**HRCT-*COOH*	13	55xmore
+G,4W,9A +AN -OH	*H*-**G**ICV**W**QDWG**A**HRCTA**N**-*COOH*	14	38xmore

dT = D-threonine
2-Nal = 2-naphthylalanine ~~2-napthylalanine~~
1-Nal = 1-naphthylalanine ~~1-napthylalanine~~
Igl = 2 indanylglycine carboxylic acid
Dht = dihydrotryptophan
Bpa = benzoylphenylalanine

Please amend Paragraph [0049] as follows:

[0003] Accordingly, modifications of Trp at position 4 (e.g., altering the structure of the side chain according to methods well known in the art), or substitutions of Trp analogs that maintain or enhance the aforementioned cation-π interaction, are contemplated in the present invention to produce analogs with even greater activity. For example, peptides comprising the tryptophan analogs 2-naphthylalanine ~~2-napthylalanine~~ (SEQ ID NOS: 7, 8), 1-naphthylalanine ~~1-napthylalanine~~ (SEQ ID NO: 9), 2-indanylglycine carboxylic acid (SEQ ID NOS: 10, 11) or dihydrotryptophan (SEQ ID NO: 12) at position 4 were all found to possess increased complement-inhibitory activity, ranging from 9-fold to 66-fold greater than Compstatin. In addition, a peptide comprising the phenylalanine analog, benzoylphenylalanine, at position 4 (SEQ ID NO: 13) possessed 55-fold greater activity that did Compstatin. It is believed that the planar two-ring compositions of these indole, naphthyl ~~napthyl~~ or dibenzoyl compounds enhances the π interaction afforded by the analog at position 4, thereby increasing the activity of the peptide. Accordingly, Trp analogs comprising two or more aromatic rings are preferred for use in the present invention. Such analogs are well known in the art and include, but are not limited to the analogs exemplified herein, as well as unsubstituted or alternatively substituted derivatives thereof. Examples of suitable analogs may be found by reference to the following publications, and many others: Beene, et al. (2002) Biochemistry 41: 10262-10269 (describing, *inter alia*, singly- and multiply-halogenated Trp analogs); Babitzke & Yanofsky (1995) J. Biol. Chem. 270: 12452-12456 (describing, *inter alia*, methylated and halogenated Trp and other Trp and indole analogs), and U.S. Patents 6,214,790, 6,169,057, 5,776,970, 4,870,097,4,576,750 and 4,299,838.